JonesResearch downgraded Deciphera to Hold from Buy with a $25.60 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer. The firm does not expect additional competing offers.
Education
About Us
Working with TipRanks
Follow Us
